Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINITY: Adjuvant T-DXd Plus Fluoropyrimidine vs Standard Chemotherapy in HER2+ Gastric/GEJ Cancer
NCT06253650Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in gastric cancer (GC), gastroesophageal junction cancer, esophageal adenocarcinoma (EAC), sponsored by Gruppo Oncologico Nord Ovest. Started Mar 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)gastroesophageal junction canceresophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06253650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253650.